iNtRON Biotechnology, Inc. (KOSDAQ:048530)
South Korea · Delayed Price · Currency is KRW 2,845.00
-45.00 (-1.56%)
Sep 22, 2026, 3:30 PM KST
iNtRON Biotechnology Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 87,887 | 102,745 | 183,560 | 291,422 | 269,879 | 709,999 | |
Market Cap Growth | -30.67% | -44.03% | -37.01% | 7.98% | -61.99% | -22.41% |
Enterprise Value | 49,465 | 67,818 | 129,604 | 224,880 | 175,332 | 642,575 |
Last Close Price | 2845.00 | 3250.00 | 5610.00 | 8631.44 | 7899.18 | 20452.36 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 47.25 | 72.99 |
Forward PE | - | 105.99 | 105.99 | 105.99 | 105.99 | 105.99 |
PS Ratio | 15.31 | 17.90 | 28.60 | 30.40 | 19.27 | 24.23 |
PB Ratio | 1.26 | 1.47 | 2.19 | 3.01 | 2.54 | 7.01 |
P/TBV Ratio | 1.28 | 1.49 | 2.23 | 3.06 | 2.58 | 7.09 |
P/FCF Ratio | - | - | - | - | 72.00 | 52.88 |
P/OCF Ratio | - | - | - | 93.48 | 45.15 | 43.10 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.62 | 11.81 | 20.19 | 23.46 | 12.52 | 21.93 |
EV/EBITDA Ratio | - | - | - | - | 1999.30 | 55.33 |
EV/EBIT Ratio | - | - | - | - | - | 63.76 |
EV/FCF Ratio | - | - | - | - | 46.78 | 47.86 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.05 | 0.02 | 0.00 | 0.30 | 0.45 |
Debt / EBITDA Ratio | - | - | - | - | 356.59 | 3.94 |
Debt / FCF Ratio | - | - | - | - | 8.34 | 3.41 |
Net Debt / Equity Ratio | -0.55 | -0.55 | -0.58 | -0.59 | -0.73 | -0.67 |
Net Debt / EBITDA Ratio | 6.45 | 6.45 | 15.13 | 41.35 | -878.94 | -5.83 |
Net Debt / FCF Ratio | 5.00 | 5.00 | 38.56 | 12.15 | -20.56 | -5.04 |
Asset Turnover | 0.07 | 0.07 | 0.07 | 0.08 | 0.10 | 0.23 |
Inventory Turnover | 2.74 | 2.74 | 2.57 | 4.20 | 4.89 | 6.01 |
Quick Ratio | 10.46 | 10.46 | 37.96 | 76.13 | 3.50 | 3.73 |
Current Ratio | 10.72 | 10.72 | 39.03 | 77.59 | 3.54 | 3.77 |
Return on Equity (ROE) | -11.66% | -11.66% | -2.87% | -9.56% | 5.50% | 10.42% |
Return on Assets (ROA) | -6.15% | -6.15% | -3.54% | -1.71% | -0.63% | 4.96% |
Return on Invested Capital (ROIC) | -22.42% | -23.73% | -13.94% | -9.51% | -3.24% | 29.38% |
Return on Capital Employed (ROCE) | -11.30% | -11.30% | -6.20% | -3.40% | -1.40% | 8.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -10.19% | -8.72% | -1.41% | -3.33% | 2.12% | 1.37% |
FCF Yield | -8.74% | -7.47% | -0.69% | -1.60% | 1.39% | 1.89% |
Buyback Yield / Dilution | 3.47% | 3.47% | 1.18% | 2.16% | -0.58% | 4.41% |